Drug intelligence / Profile preview

pediococcus acidilactici SWU-HY34

Development stage
Preclinical
Lead developer
Konkuk University
Modality
Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral
01

Overview

Pediococcus acidilactici SWU-HY34 is a specific strain of the species Pediococcus acidilactici, a Gram-positive, facultatively anaerobic, lactic acid bacterium commonly isolated from fermented foods. Strains of P. acidilactici are recognized for their probiotic properties, which include high survivability in the gastrointestinal environment, strong adhesion to intestinal epithelial cells, γ-hemolytic activity, and resistance to certain antibiotics typical of lactic acid bacteria. These strains exert health-promoting effects mainly by producing lactic acid and bacteriocins (notably pediocins), which inhibit pathogenic bacteria, as well as by modulating immune responses. Research demonstrates anti-inflammatory activity, downregulation of pro-inflammatory mediators such as inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), and suppression of cytokines like IL-1β and IL-6, primarily via modulation of nuclear factor-κB (NF-κB), mitogen-activated protein kinase (MAPK), and activator protein-1 (AP-1) signaling pathways. Clinical and animal studies on P. acidilactici strains (including other specific isolates) suggest potential benefits for gastrointestinal health, metabolic syndrome (such as hyperglycemia and hypercholesterolemia), and possibly as a therapeutic adjunct for various inflammatory diseases. SWU-HY34 refers to a particular isolate, with properties generally in line with the species, although specific published information about SWU-HY34 itself is limited[1][2][3][4][5].

Other names
pediococcus acidilactici SWU-HY34
02

Targets

FOS (Activator Protein 1)

Beyond the preview

Go deeper on pediococcus acidilactici SWU-HY34.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pediococcus acidilactici SWU-HY34.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call